Jeffrey Allen, MD
Hematology & Oncology · Post Falls, IDNPI 1104040104
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,000 of the $2,924 with a category attached, or 68.4%. GC Biopharma USA, Inc. accounts for 68.4% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $2,043, 7.5 times the $272 reported in 2019.
Across 25 payments — averaging $116.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GC Biopharma USA, Inc.$2K
- AstraZeneca$246
- E.r. Squibb & Sons, L.L.C.$147
- Seagen Inc.$115
- Genentech USA, Inc.$100
- Bristol Myers Squibb$95
- plus $222 from 9 others
Across 9 payments — averaging $610.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$5K
- Merck$500
What the payments were for
- Speaking & faculty fees$2,00068%
- Food & beverage$82828%
- Education$963%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GC Biopharma USA, Inc. | 1 | $2,000 |
| AstraZeneca | 3 | $246 |
| E.r. Squibb & Sons, L.L.C. | 5 | $147 |
| Seagen Inc. | 1 | $115 |
| Genentech USA, Inc. | 2 | $100 |
| Bristol Myers Squibb | 2 | $95 |
| Mirati Therapeutics, Inc. | 1 | $41 |
| Johnson & Johnson | 1 | $40 |
| Amgen | 2 | $34 |
| Pfizer | 2 | $28 |
| Eisai Inc. | 1 | $21 |
| AbbVie | 1 | $19 |
| AVEO Pharmaceuticals, Inc. | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,924 in reported general payments places this provider in the 55th percentile of 34 hematology & oncology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 22 | $692,110 |
| PomalystPomalidomide | 29 | $660,365 |
| BrukinsaZanubrutinib | 46 | $600,797 |
| JakafiRuxolitinib Phosphate | 28 | $584,240 |
| IbrancePalbociclib | 36 | $567,673 |
| CabometyxCabozantinib S-Malate | 13 | $405,392 |
| TagrissoOsimertinib Mesylate | 24 | $396,268 |
| ImbruvicaIbrutinib | 23 | $362,967 |
| MekinistTrametinib Dimethyl Sulfoxide | 22 | $287,269 |
| AlecensaAlectinib Hcl | 25 | $279,710 |
| TafinlarDabrafenib Mesylate | 22 | $242,343 |
| PromactaEltrombopag Olamine | 15 | $232,846 |
| ErleadaApalutamide | 12 | $181,369 |
| KisqaliRibociclib Succinate | 13 | $179,467 |
| VerzenioAbemaciclib | 12 | $160,226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $147 | $791,76443 claims |
| PfizerIbrance, Eliquis | $28 | $716,605199 claims |
| Bristol Myers SquibbRevlimid | $95 | $692,11022 claims |
| AstraZenecaTagrisso, Calquence | $246 | $475,72135 claims |
| Genentech USA, Inc.Alecensa | $100 | $279,71025 claims |
| Johnson & JohnsonErleada, Xarelto | $40 | $222,89456 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 34 hematology & oncology providers in Idaho.
Other hematology & oncology in Post Falls
- Danko MartincicPost Falls$1.1M
- Kevin MulveyPost Falls$483
- Bobby ChawlaCaldwell$1M
- Christian ShullIdaho Falls$150K
- Dane DicksonRexburg$21K
- Ian QureshiNampa$18K
- Nathan AdamsIdaho Falls$16K
- Andrew KominskyCoeur D Alene$13K
- David BartelsCoeur D Alene$11K
- Maria Cervantes FullmerIdaho Falls$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.